Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.
Thermo Fisher Scientific is significantly expanding the company’s footprint with new facilities in the United States and in Europe.
